Alzheimer’s disease affects 6.2 million Americans each year so the recent approval by the FDA of Biogen’s drug Aduhelm was met with hope by many patients and their advocates. The approval process used by the FDA, the efficacy data compiled to date, and the expected annual cost of the drug have created a swirl of controversy around the decision. In this episode of the NextGen Advisors podcast, Graham Brown and Dr. Betty Rabinowitz discuss the drug’s approval and the concerns, hopes and implications it has raised.
Meet NextGen Ambient Assist, your new AI ally that generates a structured SOAP note in seconds from listening to the natural patient/provider conversation.
Read Now